Home » Stocks » Exagen

Exagen Inc. (XGN)

Stock Price: $12.75 USD 0.04 (0.31%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 161.16M
Revenue (ttm) 40.71M
Net Income (ttm) n/a
Shares Out 12.64M
EPS (ttm) -72.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $12.75
Previous Close $12.71
Change ($) 0.04
Change (%) 0.31%
Day's Open 13.07
Day's Range 12.53 - 13.10
Day's Volume 32,331
52-Week Range 10.29 - 29.86

More Stats

Market Cap 161.16M
Enterprise Value 118.56M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 12.64M
Float 2.67M
EPS (basic) n/a
EPS (diluted) -72.27
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 111,962
Short Ratio 4.18
Short % of Float 2.14%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.96
PB Ratio 2.92
Revenue 40.71M
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 42.60M
Net Cash / Share 3.37
Gross Margin 53.01%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -13.43%
ROE -65.76%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$18.50*
(45.10% upside)
Low
17.0
Current: 12.75
High
20.0
Target: 18.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue40.3932.4426.81
Revenue Growth24.5%21.01%-
Gross Profit21.5817.0612.67
Operating Income-9.30-4.88-7.89
Net Income-12.04-8.01-25.63
Shares Outstanding3.580.060.06
Earnings Per Share-8.46-293.34-520.18
Operating Cash Flow-9.71-9.30-10.97
Capital Expenditures-0.10-0.20-0.51
Free Cash Flow-9.81-9.50-11.48
Cash & Equivalents72.0813.1611.24
Total Debt25.8524.6218.81
Net Cash / Debt46.23-11.45-7.57
Assets88.3128.8920.39
Liabilities32.6535.6225.03
Book Value55.66-112-96.68
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Exagen Inc.
Country United States
Employees 153
CEO Fortunato Ron Rocca

Stock Information

Ticker Symbol XGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: XGN

Description

Exagen Inc. operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia. The company also offers Avise SLE Prognostic, a blood test that complements Avise SLE+CT; Avise MTX, a therapeutic drug monitoring test to measure levels of methotrexate polyglutamates; and Avise HCQ, a blood test for physicians to monitor blood levels of HCQ. In addition, it is developing Anti-TNF, a blood test to monitor the levels of anti-TNF bioactivity in patients with RA; Avise SLE Monitoring, a multi-analyte panel blood test for physicians to track the disease status of their SLE patients; and Avise RA, a blood test to determine bone damage or joint erosion. The company primarily serves rheumatologists in the United States. It was formerly known as Exagen Diagnostics, Inc. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.